The study of pharmacokinetics of morpholinium 2-(5-(4-pyridyl)-4-(2-methoxyphenyl)-1,2,4-triazol-3-ylthio)acetate

  • A. G. Kaplaushenko Zaporizhzhia State Medical University
Keywords: 1,2,4-triazol, morpholinium, pharmacokinetics


Present-day medicine and pharmacy use a lot of drugs that belong to different classes of compounds. However, the creation of new high-efficient and low-toxic drugs with wide spectrum of biological activity has been and still is an important task of the pharmaceutical science. Heterocyclic compounds, namely, 1,2,4-thiazole derivatives cause great interest to this regard as potential biologically active substances.

The main purpose of the work is the synthesis of low-toxic and highly-efficient compounds as well as the search of biologically active substances among them.

The object of our study was morpholinum 2-(5-(pyridin-4-yl)-4-(2-methoxyphenyl)-1,2,4-triazol-3-ylthio)acetate (Tiometrizol). It is known that this compound is quite active in the biological aspect of the substance. In the course of our work we studied the pharmacodynamics of morpholinum 2-(5-(pyridin-4-yl)-4-(2-methoxyphenyl)-1,2,4-triazol-3-ylthio)acetate on rabbits. The analysis of the absorption spectra of serum samples, which have been obtained after administration of solution morpholinium 2-(5-(pyridin-4-yl)-4-(2-methoxyphenyl)-1,2,4-triazol-3-ylthio)acetate has been conducted and characteristic absorption band of the substance at 275 nm after 15 minutes has been registered.

It is established by spectrophotometric studying of blood and urine of animals that potential medicine Tiometrizol generates the maximum concentration in blood after intravenous injection and after 24 hours it is not detected in blood also after 32 hours it is not detected in urine of animals. That is why this non-toxic medicine can be recommended for further testing.


1. Demchenko V.K. International legal aspects of bioethics / Anthology of bioethics / Ed. Yu I. Kundiev. - Lviv: Baku, 2003 - P. 87.
2. Methodical guidelines for preclinical study of medicinal products / Ed. AV Stefanova. - K., 2001. - 567 pp.
3. Pat. to utility model No. 37922 Ukraine, IPC 2006 C07D 231/00 C07D 249/00 A61K 31/41 A61K 9/00. Morpholine 2- (5- (4-pyridyl) -4- (2-methoxyphenyl) -1,2,4-triazole-3-ylthio) acetate having anti-hypoxic activity with thermoprotective properties and its pharmaceutical forms / A.G. V. Kapusušenko, V. D. Lukianchuk, S. Ya. Rienzyak, E. G. Panasenko, A. I. Panasenko; Applicant and patent holder Zaporizhzhya State. honey. un - No. 2008 09797; Declared 28. 07. 08; Pubwished 10. 12. 08, Bull. No. 23
4. Pat. to utility model No. 37927 Ukraine, IPC 2006 C07D 231/00 C07D 249/00 A61K 31/41. Morpholine 2- (5- (4-pyridyl) -4- (2-methoxyphenyl) -1,2,4-triazole-3-ylthio) acetate exhibiting antioxidant and detoxifying activity / A. G. Kaploushenko, V. D Lukianchuk, OI Panasenko, Ye.G. Knysh, L.V. Chadov, N.V. Rysukhin; Applicant and patent holder Zaporizhzhya State. honey. un - № u 2008 09816; Declared 28. 07. 08; Pubwished 10. 12. 08, Bull. No. 23
5. Kaplushenko A.G., Panasenko O.I., Knysh Y. G. Development of the method of quantitative analysis of the main substance and possible impurities in the substance of morpholines 2- (5- (4-pyridyl) -4- (2-methoxyphenyl) - 1,2,4-triazole-3-ylthio) acetate // Pharmac. journ - 2010. - No. 2 - C. 49-54.
How to Cite
Kaplaushenko, A. G. (2019). The study of pharmacokinetics of morpholinium 2-(5-(4-pyridyl)-4-(2-methoxyphenyl)-1,2,4-triazol-3-ylthio)acetate. Farmatsevtychnyi Zhurnal, (6), 88-92. Retrieved from